Molecular characterization and therapeutic reaction to dasatinib in a CML patient harboring a novel e8a2 BCR-ABL1 transcript with a somatic mutation in TP53BP2 and cadherin-10 genes.

The article presents a case study of a reaction to the dasatinib drug in a 49-year-old man with chronic myeloid leukemia (CML) harboring a e8a2 BCR-ABL1 transcript gene with a somatic mutation of TP53BP2 and cadherin-10 (CDH10) gene. The patient was diagnosed with CML harboring the e8a2 transcript, and his variant BCR-ABL1:ABL1 ratio was revealed. He obtained complete remission at the molecular and hematological level.